Found: 30
Select item for more details and to access through your institution.
Highlights.
- Published in:
- 2018
- Publication type:
- Abstract
In This Issue.
- Published in:
- 2018
- Publication type:
- Abstract
Influence of Diabetes on Antiplatelet Drug Efficacy.
- Published in:
- 2018
- By:
- Publication type:
- Letter to the Editor
An Industry Perspective on the 2017 EMA Guideline on First‐in‐Human and Early Clinical Trials.
- Published in:
- Clinical Pharmacology & Therapeutics, 2018, v. 103, n. 4, p. 566, doi. 10.1002/cpt.984
- By:
- Publication type:
- Article
Population Pharmacokinetics of Durvalumab in Cancer Patients and Association With Longitudinal Biomarkers of Disease Status.
- Published in:
- Clinical Pharmacology & Therapeutics, 2018, v. 103, n. 4, p. 631, doi. 10.1002/cpt.982
- By:
- Publication type:
- Article
Poly‐pharmacokinetic Study of a Multicomponent Herbal Medicine in Healthy Chinese Volunteers.
- Published in:
- Clinical Pharmacology & Therapeutics, 2018, v. 103, n. 4, p. 692, doi. 10.1002/cpt.784
- By:
- Publication type:
- Article
ASCPT NEWS.
- Published in:
- Clinical Pharmacology & Therapeutics, 2018, v. 103, n. 4, p. 547, doi. 10.1002/cpt.1043
- Publication type:
- Article
Farewell to Our Good Friend, Outstanding Mentor, and Colleague Darrell R. Abernethy (1949–2017).
- Published in:
- 2018
- By:
- Publication type:
- Obituary
Patient‐Centered Reverse Translation.
- Published in:
- 2018
- Publication type:
- Correction Notice
Lucerastat, an Iminosugar for Substrate Reduction Therapy: Tolerability, Pharmacodynamics, and Pharmacokinetics in Patients With Fabry Disease on Enzyme Replacement.
- Published in:
- Clinical Pharmacology & Therapeutics, 2018, v. 103, n. 4, p. 703, doi. 10.1002/cpt.790
- By:
- Publication type:
- Article
Real‐life Use of Anticoagulants in Venous Thromboembolism With a Focus on Patients With Exclusion Criteria for Direct Oral Anticoagulants.
- Published in:
- Clinical Pharmacology & Therapeutics, 2018, v. 103, n. 4, p. 684, doi. 10.1002/cpt.781
- By:
- Publication type:
- Article
Clinical Pharmacogenetics Implementation Consortium Guideline for <italic>HLA</italic> Genotype and Use of Carbamazepine and Oxcarbazepine: 2017 Update.
- Published in:
- Clinical Pharmacology & Therapeutics, 2018, v. 103, n. 4, p. 574, doi. 10.1002/cpt.1004
- By:
- Publication type:
- Article
Response to “Influence of Diabetes on Antiplatelet Drug Efficacy”.
- Published in:
- 2018
- By:
- Publication type:
- Letter to the Editor
Population Modeling of Tumor Kinetics and Overall Survival to Identify Prognostic and Predictive Biomarkers of Efficacy for Durvalumab in Patients With Urothelial Carcinoma.
- Published in:
- Clinical Pharmacology & Therapeutics, 2018, v. 103, n. 4, p. 643, doi. 10.1002/cpt.986
- By:
- Publication type:
- Article
Rapid Advances in Immunotherapy to Treat Cancer.
- Published in:
- Clinical Pharmacology & Therapeutics, 2018, v. 103, n. 4, p. 540, doi. 10.1002/cpt.985
- By:
- Publication type:
- Article
A Population Pharmacokinetic Model Incorporating Saturable Pharmacokinetics and Autoinduction for High Rifampicin Doses.
- Published in:
- Clinical Pharmacology & Therapeutics, 2018, v. 103, n. 4, p. 674, doi. 10.1002/cpt.778
- By:
- Publication type:
- Article
Individualized Dosing Algorithms and Therapeutic Monitoring for Antiepileptic Drugs.
- Published in:
- Clinical Pharmacology & Therapeutics, 2018, v. 103, n. 4, p. 663, doi. 10.1002/cpt.777
- By:
- Publication type:
- Article
Response to “Antiretroviral Therapy With Efavirenz in HIV‐Infected Pregnant Women: Understanding the Possible Mechanisms for Drug–Drug Interaction”.
- Published in:
- 2018
- By:
- Publication type:
- Letter to the Editor
Antiretroviral Therapy With Efavirenz in HIV‐Infected Pregnant Women: Understanding the Possible Mechanisms for Drug–Drug Interaction.
- Published in:
- 2018
- By:
- Publication type:
- Letter to the Editor
The Evolution and Future of CAR T Cells for B‐Cell Acute Lymphoblastic Leukemia.
- Published in:
- Clinical Pharmacology & Therapeutics, 2018, v. 103, n. 4, p. 591, doi. 10.1002/cpt.950
- By:
- Publication type:
- Article
Designing In and Around Tolerability Considerations for Immunotherapy Combinations.
- Published in:
- Clinical Pharmacology & Therapeutics, 2018, v. 103, n. 4, p. 558, doi. 10.1002/cpt.945
- By:
- Publication type:
- Article
Promoting Safe Early Clinical Research of Novel Drug Candidates: A European Union Regulatory Perspective.
- Published in:
- Clinical Pharmacology & Therapeutics, 2018, v. 103, n. 4, p. 564, doi. 10.1002/cpt.899
- By:
- Publication type:
- Article
Dose Rationalization of Pembrolizumab and Nivolumab Using Pharmacokinetic Modeling and Simulation and Cost Analysis.
- Published in:
- Clinical Pharmacology & Therapeutics, 2018, v. 103, n. 4, p. 582, doi. 10.1002/cpt.875
- By:
- Publication type:
- Article
Diagnosis Drift and Its Contribution to Polypharmacy.
- Published in:
- Clinical Pharmacology & Therapeutics, 2018, v. 103, n. 4, p. 556, doi. 10.1002/cpt.858
- By:
- Publication type:
- Article
Issue Information.
- Published in:
- Clinical Pharmacology & Therapeutics, 2018, v. 103, n. 4, p. 531, doi. 10.1002/cpt.830
- Publication type:
- Article
Critical Issues and Optimized Practices in Quantification of Protein Abundance Level to Determine Interindividual Variability in DMET Proteins by LC‐MS/MS Proteomics.
- Published in:
- Clinical Pharmacology & Therapeutics, 2018, v. 103, n. 4, p. 619, doi. 10.1002/cpt.819
- By:
- Publication type:
- Article
Genetic Variants in <italic>HSD17B3</italic>, <italic>SMAD3</italic>, and <italic>IPO11</italic> Impact Circulating Lipids in Response to Fenofibrate in Individuals With Type 2 Diabetes.
- Published in:
- Clinical Pharmacology & Therapeutics, 2018, v. 103, n. 4, p. 712, doi. 10.1002/cpt.798
- By:
- Publication type:
- Article
Psychedelic Drugs as Therapeutics: No Illusions About the Challenges.
- Published in:
- Clinical Pharmacology & Therapeutics, 2018, v. 103, n. 4, p. 561, doi. 10.1002/cpt.776
- By:
- Publication type:
- Article
Analgesic Plasma Concentrations of Oxycodone After Surgery for Breast Cancer—Which Factors Matter?
- Published in:
- Clinical Pharmacology & Therapeutics, 2018, v. 103, n. 4, p. 653, doi. 10.1002/cpt.771
- By:
- Publication type:
- Article
Comparison of the Guidelines of the Clinical Pharmacogenetics Implementation Consortium and the Dutch Pharmacogenetics Working Group.
- Published in:
- Clinical Pharmacology & Therapeutics, 2018, v. 103, n. 4, p. 599, doi. 10.1002/cpt.762
- By:
- Publication type:
- Article